Novavax, Moderna Gain as Becton Dickinson Plans $3 Billion U.S. Investment

Moderna and Novavax posted strong weekly gains as plague-related events affected pandemic-era biotechnology stocks, while Becton Dickinson outlined a $3 billion U.S. manufacturing investment and Viatris agreed to acquire Pacira BioSciences for $1.65 billion. Moderna gained nearly 7% during the week ended Oct. 11. Moderna’s shares rose just over 14% on Oct. 9 to close at $225 and reach a new 52-week high. The move extended the stock’s gains during a week when health care shares advanced alongside the broader U.S. market. Novavax rose more than 20% during the week.

Source: TokenPost